drugset / Trial / NCT00891007
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
RandomizedParallel-groupOpen-labelPrevention
Summary
Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-07
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVA mBN85B | Vaccine | 1e+07 unknown | Subcutaneous |
| Subject | MVA mBN85B | Vaccine | 1e+08 unknown | Subcutaneous |
| Comparator | Rouvax | Vaccine | 0.5 ml | Subcutaneous |
| Comparator | Rouvax | Vaccine | 1000 unknown | Subcutaneous |